AP NEWS

Hemophilia A Therapeutics - Global Market Outlook to 2023 with Bayer, CSL, Novo Nordisk, Pfizer and Shire Dominating - ResearchAndMarkets.com

January 7, 2019

DUBLIN--(BUSINESS WIRE)--Jan 7, 2019--The “Global Hemophilia A Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.

Emerging novel convenient approaches to drive market growth

Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder.

Rising prevalence of hemophilia A

Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.

High costs of hemophilia A therapeutics

High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.

Key Players

Bayer CSL Novo Nordisk Pfizer Shire

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

Market definition Market sizing 2018 Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product Comparison by product Recombinant therapies - Market size and forecast 2018-2023 Plasma-derived therapies - Market size and forecast 2018-2023 Hormonal therapies - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

On demand treatment Prophylactic treatment Inhibitor treatment

PART 10: GEOGRAPHIC LANDSCAPE

Geographic segmentation Geographic comparison Americas - Market size and forecast 2018-2023 EMEA - Market size and forecast 2018-2023 APAC - Market size and forecast 2018-2023 Key leading countries Market opportunity

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview Landscape disruption

PART 14: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Bayer CSL Novo Nordisk Pfizer Shire

For more information about this report visit https://www.researchandmarkets.com/research/bkvl62/hemophilia_a?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005513/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/07/2019 06:07 AM/DISC: 01/07/2019 06:07 AM

http://www.businesswire.com/news/home/20190107005513/en

AP RADIO
Update hourly